Osteoarthritis
-
Sports Medicine
Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study
Implantable shock absorber demonstrates clinically meaningful pain relief and functional improvement in data presented at OSET September 23, 2022 FREMONT,…
Read More » -
Sports Medicine
Moximed Raises $40 Million to Advance World’s First Implantable Shock Absorber for Knee Osteoarthritis
August 16, 2022 FREMONT, Calif.–(BUSINESS WIRE)–Moximed, a medical device company on a mission to improve the standard of care for…
Read More » -
Biologics
Lipogems® Receives IDE Approval From The U.S. FDA To Begin A Pivotal Clinical Study On The Safety And Effectiveness Of The Lipogems System For The Treatment of Knee Osteoarthritis
ATLANTA , June 10, 2022 /PRNewswire/ — Lipogems is pleased to announce the unconditional approval by the U.S. Food and Drug Administration (FDA) to…
Read More » -
Biologics
First Subjects Randomized and Dosed in the U.S. under Phase III Pivotal Trial for the Treatment of Pain Associated with Knee OA
Ongoing trial to assess the potential of Zilosul™ to address unmet medical need in OA which affects more than 72 million…
Read More » -
Extremities
HSS Study Tackles Concomitant Limb Deformity, End-Stage Ankle OA
Elizabeth Hofheinz, M.P.H., M.Ed New work from Hospital for Special Surgery (HSS) in New York has looked at eight patients…
Read More » -
Recon
New Invention Stops or Delays the Progression of Osteoarthritis of the Knee
NEW YORK, April 1, 2021 /PRNewswire/ — New York Bone & Joint Specialists is at the forefront of orthopedic technology, with an exciting…
Read More » -
Extremities
Ensemble Orthopedics Announces Successful First Implantation Of Its Pyrocarbon Interpositional CMC
AUSTIN, Texas, March 25, 2021 /PRNewswire/ — Ensemble Orthopedics, Inc. announced today the first implantation of the FDA-cleared Ensemble CMC™, the first implant…
Read More » -
Recon
Depressed Patients: 225% More Likely to Receive Opioids for Knee OA!
Elizabeth Hofheinz, M.P.H., M.Ed. There is a lot to unpack in a recent massive study of patients with knee osteoarthritis…
Read More » -
Recon
Bilateral Shoulder Arthroplasty: Men With OA More Likely to Request Second Shoulder Arthroplasty Within One Year
Elizabeth Hofheinz, M.P.H., M.Ed. In a retrospective review of 332 patients who underwent bilateral anatomic (TSA) or reverse (RSA) shoulder…
Read More » -
Biologics
Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee
FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with…
Read More » -
Biologics
Bioventus Receives Authorization to Proceed Under Investigational New Drug Application for Clinical Trial of Placental Tissue Particulate (PTP-001) for the Treatment of Knee OA
November 18, 2020 DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a leader in Solutions For Innovative Healing, received authorization to proceed under its investigational…
Read More » -
Recon
Total Joint Replacement and the Impact on Future Falls in Osteoarthritis Patients
ROSEMONT, Ill., Oct. 16, 2020 /PRNewswire/ — Patients who have had a total joint arthroplasty (TJA) demonstrate excellent long-term outcomes with increased…
Read More » -
Recon
The LSU Integrated Musculoskeletal Biobank (LIMB): Going to Extremes for ALL Patients
by Elizabeth Hofheinz, M.P.H., M.Ed. The Department of Orthopaedic Surgery at Louisiana State University (LSU) Health – New Orleans is…
Read More » -
Biologics
Bioventus Reaches Milestone with 2 Million DUROLANE® Treatments Worldwide
September 22, 2020 DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing…
Read More » -
Biologics
New Approach to Treating Osteoarthritis Advances
NEW YORK, Aug. 10, 2020 /PRNewswire/ — Injections of a natural “energy” molecule prompted regrowth of almost half of the cartilage lost…
Read More »